Fluoropyrimidine

Phase 2Small molecule

Roche

Fluoropyrimidine is one of 120 small molecule programs targeting Cardiotoxicity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

CardiotoxicityActive, not recruiting

ChemotherapyUnknown status

MalignanciesEnrolling by invitation

Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal CancerActive, not recruiting

EffectivenessCompleted

CardiotoxicityPreclinical

Active, not recruiting

ChemotherapyPreclinical

Unknown status

MalignanciesPhase 2

Enrolling by invitation

Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal CancerPreclinical

Active, not recruiting

EffectivenessPreclinical

Completed

Competition

Competitive Landscape

109 competitors in Chemotherapy

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

20 2

Eloxatin

Teva

Phase 3

13 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

29 4

Cytosar

Teva

Phase 3

11 5

Avastin

Roche

Phase 3

11 6

Vepesid

AAvyxa

Phase 3

22 7

Opdivo

Bristol-Myers Squibb

Phase 3

7 8

Imfinzi

AstraZeneca

Phase 3

7 9

Camptosar

Pfizer

Phase 3

7 10

Gemzar

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal Cancer

NCT05609370

Q1 2028

Phase 1Recruiting

Autoimmune

NCT03816345

Q3 2029

Phase 3Active, not recruiting

Metastatic Colorectal Cancer

NCT04188145

PreclinicalRecruiting

Esophageal Cancer

NCT07818018

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer3 trials

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer

Terminated·UUniversity of Alabama at Birmingham·Phase 2·NCT00033306·2 enrolled

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Completed· Roche logo

Roche·Phase 2·NCT02291289·1,044 enrolled

A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer

Active, not recruiting·CCentre Hospitalier Universitaire Dijon·Phase 3·NCT04188145·400 enrolled

Gastric Cancer1 trial

Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03023436·220 enrolled

Adenocarcinoma1 trial

A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

Unknown status·BBelgian Group of Digestive Oncology·Phase 3·NCT04257461·30 enrolled

Chemotherapy1 trial

Improving the Safety of Fluoropyrimidine-based Chemotherapy

Unknown status·TThe Netherlands Cancer Institute·N/A·NCT04194957·1,440 enrolled

Malignancies1 trial

Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies

Enrolling by invitation·UUniversity of Vermont Medical Center·Phase 2·NCT06648785·20 enrolled

6 more indications

Colorectal Cancer1 trial

TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00399750·373 enrolled

Effectiveness1 trial

Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines

Completed·TThe Netherlands Cancer Institute·N/A·NCT02324452·1,103 enrolled

Cardiotoxicity1 trial

Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study

Enrolling by invitation·HHelsinki University Central Hospital··NCT04260269·200 enrolled

Autoimmune1 trial

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03816345·300 enrolled

Esophageal Cancer1 trial

A Phase 1b/II Study of Intratumoral CD40 Agonist 2141-V11 in Combination With Anti PD-1 and 5-Fluorouracil Therapy in Patients With Advanced Gastroesophageal Adenocarcinoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT07818018·30 enrolled

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1 trial

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Active, not recruiting· BeiGene logo

BeiGene·Preclinical·NCT05609370·113 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Fluoropyrimidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluoropyrimidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluoropyrimidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

Fluoropyrimidine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q3 2029

Trials by Indication[1]

Metastatic Colorectal Cancer3 trials

Gastric Cancer1 trial

Adenocarcinoma1 trial

Chemotherapy1 trial

Malignancies1 trial

Colorectal Cancer1 trial

Effectiveness1 trial

Cardiotoxicity1 trial

Autoimmune1 trial

Esophageal Cancer1 trial

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News